menu

NEWS

5AM VENTURES RAISES $285 MILLION LIFE SCIENCE VENTURE CAPITAL FUND

 

Menlo Park, CA, May 31, 2016 – 5AM Venture Management, LLC (5AM) of Menlo Park, CA and Boston, MA is pleased to announce the closing of 5AM Ventures V, L.P., a $285 million venture capital fund focused on the building of life science companies.  The capital was raised from a broad range of existing and new institutional investors including endowments, family offices, foundations, funds-of-funds and pension funds.  Since inception, 5AM has raised ~$1 billion for investments in innovative life science companies.

Created by successful industry executives and experienced venture capitalists, the 5AM team takes a focused, hands-on approach to company building. 5AM will continue to target early-stage life science companies with investments focused on the discovery and development of therapeutics, drug delivery technologies and research instruments and reagents.    Within each sector, the firm will invest across various therapeutic areas and will consider opportunities based on innovative platform technologies, corporate spinoffs and products with shorter development cycles.

5AM’s investment team is led by Managing Partners Kush Parmar, M.D., Ph.D., Scott Rocklage, Ph.D., and Andy Schwab.  John Diekman, Ph.D., who co-founded 5AM in 2002, is a Founding Partner. Other team members include: Partner Paul Stone, J.D.; Venture Partners Brian Daniels, M.D., Peter Kim, Ph.D., Mason Freeman, M.D., Richard Ulevitch, Ph.D. & Jim Young, Ph.D.; Associates Mira Chaurushiya, Ph.D., Hannah Chang, M.D., Ph.D., & Arjun Goyal, M.D., Executives in Residence Yujiro Hata & Lou Tartaglia, Ph.D., and Vice President, Finance, Jenny Lee.

 

About 5AM Ventures

Founded in 2002, 5AM Ventures actively invests in next-generation life science companies.  With ~$1 billion under management, 5AM has invested in 54 companies and successful exits include DVS Sciences (acquired by Fluidigm), Envoy Therapeutics (acquired by Takeda), Flexion Therapeutics (Nasdaq: FLXN), Ikaria (acquired by Mallinckrodt), Ilypsa (acquired by Amgen), Incline Therapeutics (acquired by The Medicines Company), Marcadia Biotech (acquired by Roche), Novira Therapeutics (acquired by J&J), Pearl Therapeutics (acquired by AstraZeneca) and Relypsa (Nasdaq: RLYP). For more information, please visit www.5amventures.com.

 

Contact:
5AM Venture Management LLC
Andrew Schwab, Managing Partner
Phone: +1-650-233-8604
Email: [email protected]